論文・技術情報追加のお知らせ

1. A real-world investigation of drug-induced hyperglycemia and diabetes mellitus in pediatric populations using the FDA adverse event reporting system.

小児の薬剤性高血糖/糖尿病リスク信号をFAERSで抽出

対象DB：FAERS

2. Real-world data on the abuse potential of medications for the treatment of insomnia: a disproportionality analysis of the FAERS database.

不眠症治療薬の乱用傾向をFAERSで解析

対象DB：FAERS

3. Proton Pump Inhibitors and Disproportionate Reporting of Acute Kidney Injury and Tubulointerstitial Nephritis: A FAERS Pharmacovigilance Study, 2020-2025.

PPIの急性腎障害・間質性腎炎報告をFAERSで評価

対象DB：FAERS

4. Hematologic safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: insights from platelet-related signal detection in the FAERS database.

iTTP治療薬カプラシズマブの血液安全性信号を検出

対象DB：FAERS

5. Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database.

抗がん薬タルラタマブの有害事象をFAERSで総合評価

対象DB：FAERS

6. Haemorrhage-related adverse events associated with nintedanib: a pharmacovigilance study based on the FAERS database.

ニンテダニブ関連の出血性有害事象信号をFAERSで解析

対象DB：FAERS

7. Risk signal assessment of Tdap vaccine use alone by pregnant women: An updated pharmacoepidemiological study.

妊婦単独Tdap接種のリスク信号を最新データで検討

対象DB：FAERS,VAERS

8. Clinical profiles and risk predictors of drug-induced liver injury from pirfenidone and nintedanib used to treat idiopathic pulmonary fibrosis: a real-world analysis of a tertiary Chinese hospital cohort combined with FAERS data mining.

IPF薬ピル/ニンの薬剤性肝障害を病院コホート+FAERSで解析

対象DB：FAERS

9. Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy.

VEGF/VEGFR阻害薬とTMAの前臨床-臨床ギャップを整理

対象DB：FAERS,VigiBase

10. Drug-associated Takotsubo syndrome risk profiling: a global pharmacovigilance study.

薬剤関連たこつぼ心筋症のリスクを世界PVでプロファイル

対象DB：FAERS

11. Deep exploration of sotorasib-related hepatobiliary AEs: Based on FDA Adverse Event reporting system.

ソトラシブの肝胆道系有害事象をFAERSで深掘り

対象DB：FAERS

12. Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system.

フォンダパリヌクス関連有害事象の報告信号をFAERSで解析

対象DB：FAERS

13. ROOT CAUSE ANALYSIS OF SENTINEL EVENTS IN A PUBLIC HOSPITAL: A MIXED-METHOD STUDY ON REPORTING CULTURE AND CONTRIBUTING FACTORS.

公立病院のセンチネル事象原因と報告文化を混合法で分析

対象DB：FAERS

14. Age and Gender Heterogeneity in Adverse Drug Reactions Associated with Hemp Use: Evidence from the FDA Pharmacovigilance Data in the Last Two Decades.

大麻(ヘンプ)使用の副作用を年齢・性別差でFAERS解析

対象DB：FAERS

15. Exploring the risk of depression and suicide/self-injury in patients receiving GLP-1RAs combined with metformin versus GLP-1RAs monotherapy: a real-word analysis of FAERS database.

GLP-1RA+メトホルミンの抑うつ/自傷リスクをFAERS比較

対象DB：FAERS

16. Analysis of ASMs and male infertility using the FDA adverse event reporting system (FAERS).

抗てんかん薬と男性不妊の関連をFAERSで解析

対象DB：FAERS

17. Assessing the real-world safety of sparsentan for immunoglobulin A nephropathy: insights from a comprehensive analysis of FAERS database.

IgA腎症薬スパーセンタンの安全性をFAERSで評価

対象DB：FAERS

18. Atrial fibrillation associated with tyrosine kinase inhibitors: A case-control study of real-world pharmacovigilance data.

チロシンキナーゼ阻害薬と心房細動の関連を実データ解析

対象DB：FAERS

19. Thrombotic and Hemorrhagic Adverse Events of Direct Oral Anticoagulants: An Analysis of Sex-Related Differences Using Food and Drug Administration Adverse Event Reporting System.

DOACの血栓/出血有害事象の性差をFAERSで検討

対象DB：FAERS

20. Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): A pharmacovigilance disproportionality analysis of FAERS data.

SSRIによる男性性機能障害の報告信号をFAERS解析

対象DB：FAERS

21. Oral iron preparations: gastrointestinal adverse events and medication adherence in female patients with iron deficiency anemia.

経口鉄剤の消化器副作用と服薬継続性を女性IDAで検討

対象DB：FAERS

22. Real-world study of adverse events associated with ceftazidime/avibactam based on the U.S. Food and Drug Administration adverse event reporting system database.

セフタジジム/アビバクタム有害事象をFAERSで実態解析

対象DB：FAERS

23. Post-marketing safety of pentosan polysulfate sodium: a 21-year pharmacovigilance analysis of the FAERS database.

ペントサン多硫酸Naの市販後安全性を21年FAERSで評価

対象DB：FAERS

24. [Data mining and toxicity profile analysis of immune checkpoint inhibitor-related skin toxicity events based on FAERS].

免疫チェックポイント阻害薬の皮膚毒性をFAERSで網羅解析

対象DB：FAERS

25. Evaluating adverse events reported for non-steroidal anti-inflammatory drugs in osteoarthritis: a real-world pharmacovigilance study.

変形性関節症でNSAIDs有害事象を実臨床PVで評価

対象DB：FAERS

26. Pharmacovigilance Assessment of PD-1 Antibody Therapy in Head and Neck Cancer: Risk Factor Analysis Using FAERS Database.

頭頸部がんPD-1抗体療法の副作用因子をFAERSで解析

対象DB：FAERS

27. Safety profile of progesterone: Insights from an FDA Adverse Event Reporting System (FAERS)-based pharmacovigilance study.

プロゲステロンの安全性プロファイルをFAERSで検討

対象DB：FAERS

28. Safety Assessment of Budesonide/Formoterol: Real-World Pharmacovigilance Analysis Using the FAERS, JADER, and CVAR Databases.

ブデソニド/ホルモテロール安全性をFAERS等3DBで解析

対象DB：CVAR,FAERS,JADER

29. Keloids as a rare complication of voluntary medical male circumcision: findings from PEPFAR's notifiable adverse events reporting system.

男性包茎手術後のケロイド発生をPEPFAR報告で検討

対象DB：FAERS

30. Accidental secondary pentobarbital intoxication in small domestic animals and wild birds in Europe.

動物・野鳥の二次ペントバルビタール中毒事例を欧州調査

対象DB：EudraVigilance

31. AI-Enabled Surveillance and Modelling for Counterfeit Botulinum Toxin A: Risk Projection, Patient Safety, and Systemic Reform of Pharmacovigilance.

偽造ボツリヌス毒素AをAI監視しリスク予測とPV改革提言

対象DB：EudraVigilance

32. Nocturnal emissions or wet dreams: modern evidence from a systematic scoping review.

夢精の最新知見を体系的スコーピングレビューで整理

対象DB：EudraVigilance

33. Differential musculoskeletal outcome reporting in patients receiving bempedoic acid or atorvastatin: a disproportionality analysis using the EudraVigilance database.

ベンペド酸/アトルバの筋骨格系報告差をEVで解析

対象DB：EudraVigilance

34. Drugs associated with generalized non-allergic pruritus: A World Health Organization pharmacovigilance database analysis.

全身性非アレルギー性掻痒と関連薬をWHO PVで抽出

対象DB：VigiBase

35. Impact of Chemotherapy and Anticancer Agent Type on 30-Day All-Cause In-Hospital Mortality of Venous Thromboembolism Patients With Cancer in Japan.

日本のがん合併VTEで化学療法種別と30日院内死亡を評価

対象DB：DPC

36. Smoking increases the risk of early postoperative infection after elective total hip arthroplasty: Evidence from a Nationwide Japanese database.

喫煙が人工股関節術後早期感染リスクを上げると全国DBで示唆

対象DB：DPC

37. Annual Trends and Regional Disparities in Transvenous Lead Extractions in Japan: Insights From the Nationwide Japanese Registry of All Cardiac and Vascular Diseases-Diagnostic Procedure Combination Data.

日本の経静脈リード抜去の年次推移と地域差を全国DBで解析

対象DB：DPC

38. Patient characteristics, antibiotic use, and in-hospital outcomes in patients with ischaemic colitis: A nationwide retrospective cohort study.

虚血性大腸炎の患者像・抗菌薬使用と院内転帰を全国DBで解析

対象DB：DPC

39. Incidence and treatment patterns of acute retinal necrosis: a nationwide population-based cohort study.

急性網膜壊死の発症率と治療実態を全国コホートで把握

対象DB：NDB

40. Trends in the incidence of secondary hip fractures and osteoporosis treatment in Japan (FY2012-FY2023).

日本の二次股関節骨折と骨粗鬆治療の推移(2012-2023)

対象DB：NDB

41. Sex Differences and Age Distributions in Invasive Treatments for Chalazion and Hordeolum in Japan: A 9-Year Nationwide Claims Study.

霰粒腫・麦粒腫の侵襲治療の性差/年齢分布を全国請求で解析

対象DB：NDB

42. Association of symptoms at heart failure diagnosis with hospitalisation and mortality at 6 and 12 months: a retrospective cohort study using UK primary care health records.

心不全診断時症状と6/12か月入院・死亡の関連を記録DB解析

対象DB：CPRD

43. Relationships between alcohol use and dementia: protocol for an observational study in the UK Clinical Practice Research Datalink.

アルコール使用と認知症の関連をCPRDで観察研究する計画

対象DB：CPRD

44. Performance of the Self-Controlled Case Series for Drug Safety Signal Detection: A Multi-Database Study.

薬剤安全性検出におけるSCCS法の性能を多DBで比較検証

対象DB：CPRD

45. Exploring spillover effects following surgical de-implementation: An observational evaluation of primary care, referrals, and time to surgical intervention following reductions in the use of tonsillectomy and Dupuytren's contracture.

手術の廃止介入後の波及効果を紹介・待機時間などで観察評価

対象DB：CPRD

46. Incidence and survival of head and neck cancers in the United Kingdom 2000-2021.

英国の頭頸部がん発症率と生存の推移(2000-2021)を解析

対象DB：CPRD

47. Linking primary care data from clinical practice research datalink to secondary care and other health-related patient data: update and implications.

CPRDと二次医療等のデータ連結の更新と活用影響を整理

対象DB：CPRD

48. Prescribing of medication to prevent glucocorticoid harms in patients with Polymyalgia Rheumatica: a cross-sectional study and two emulated target trials in the Clinical Practice Research Datalink Aurum.

PMR患者のステロイド有害事象予防薬処方を横断+模擬試験で評価

対象DB：CPRD

49. A letter intervention to GPs practices to promoting prescription uptake in school-age children with asthma during summer holidays (TRAINS study): a pragmatic cluster randomised controlled trial.

夏休み中の小児喘息予防薬処方促進をGP宛レターでRCT検証

対象DB：CPRD

50. The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer.

乳がん女性で既存2型糖尿病が死亡に与える影響を解析

対象DB：CPRD

51. Quantifying selection bias due to unobserved patients in pharmacoepidemiologic studies of severe COVID-19 cohorts.

重症COVID研究の未観測患者による選択バイアスを定量化

対象DB：CPRD

52. Long-Term Outcomes and Therapeutic Strategies for Newly Diagnosed Crohn's Disease in the Biologic Era: A Nationwide Claims-Based Study from Japan.

生物学的製剤時代の新規クローン病長期転帰を全国請求で解析

対象DB：DeSC

53. Hospitalization after Initial Telemedicine Versus in-Person Consultation for Outpatients with Respiratory or Digestive Diseases: A Retrospective Cohort Study.

遠隔診療と対面初診後の入院リスクを呼吸器/消化器で比較

対象DB：DeSC

54. Appropriate definition of childbirth using Japanese administrative database: a cross-sectional cohort validation study.

日本の行政DBで分娩定義の妥当性を検証する横断研究

対象DB：DeSC